... and there's nothing to say that we won't take the autologous...

... and there's nothing to say that we won't take the autologous route into the clinic sooner or latter. For all we know, MDA's particular binder didn't perform as well as PTX expected or that the agenda was for MDA to derive the data they wanted to know about OmniCAR. Perhaps the collab served its purpose in another way to be of much value for both parties later down the track when personalised treatment is the norm in the commercial market. We just need some light on the matter from the co. and sooner the better.